Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Ballinger, Angela E ^a   Palmer, Suetonia C ^a   Nistor, Ionut ^b,c   Craig, Jonathan C ^d,e   Strippoli, Giovanni F M ^d,e,f,g,h,i  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f UNIVERSITY OF BARI   (Italy)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h Diaverum   (Sweden)

ⁱ UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; NAPHTHALENE DERIVATIVE; PTH PROTEIN, HUMAN;

ALL CAUSE MORTALITY; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GRADE CRITERIA; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY TRANSPLANTATION; META ANALYSIS; MORTALITY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW; VOMITING; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPLICATION; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC;

CALCIMIMETIC AGENTS; CALCIUM; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 84925225057     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006254.pub2     Document Type: Review

References (163)

1. Charytan C, Corry D, Roppolo M, Ling X, Droge J, Fishbane S. Assessing the use of the calcimimetic cinacalcet with low dose vitamin D versus escalating doses of vitamin D alone in the treatment of secondary hyperparathyroidism (HPT) - The ACHIEVE Study [abstract no: 39]. American Journal of Kidney Diseases 2007;49(4):A34. [CENTRAL: CN-00615830]
2. Charytan C, Wetmore J, Moustafa M, Martinez C, Stewart T, Ling X, et al. Efficacy of treatments targeting the calcium-sensing receptor (CaR) and vitamin D receptor (VDR) in controlling parathyroid hormone (PTH) in hemodialysis (HD) patients: cinacalcet HCI plus low-dose vitamin D vs flexible vitamin D alone [abstract no: SU-PO812]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):764A.
3. Fishbane S, Shapiro W, Corry D, Rappaport K, Vicks S, Ling X, et al. A comparison of cinacalcet HCI and low-dose vitamin D vs escalating doses of vitamin D alone - the ACHIEVE study [abstract no: PUB354]. Journal of the American Society of Nephrology 2006;17(Abstracts):891A. [CENTRAL: CN-00615831]
4. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(6):1718-25. [MEDLINE: 18945995]
5. Fishbane S, Vicks S, Ling X, Turner S, Charytan C. Cinacalcet with low dose vitamin D provides improved control of parathyroid hormone, calcium, and calcium-phosphorus product in hemodialysis patients with secondary hyperparathyroidism compared with vitamin D alone [abstract no: SaP383]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi363. [CENTRAL: CN-00671779]
6. Fishbane S, Wetmore J, Moustafa M, Martinez C, Ling X, Turner S, et al. Treatment with cinacalcet HC1 and concurrent low-dose vitamin D improved management of secondary hyperparathyroidism (SHPT) compared with vitamin D alone [abstract no: SU-FC100]. Journal of the American Society of Nephrology 2007;18(Abstracts):89A.
7. Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. American Journal of Kidney Diseases 2010;56(6):1108-16. [MEDLINE: 20951487]
8. Wetmore JB, Liu S, Krebill R, Menard R, Quarles D. Treatment with cinacalcet plus vitamin D results in lower FGF23 levels than vitamin D alone [abstract no: SA-PO2779]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):739A.
9. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(1):110-6. [MEDLINE: 19965548]
10. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation 2010;25(6):1916-23. [MEDLINE: 20110249]
11. Floege J, Sprague S, Droge J, Banos A, Chertow G. ADVANCE: the effect of cinacalcet + low-dose vitamin D on vascular calcification in hemodialysis patients - methods [abstract no: 60]. American Journal of Kidney Diseases 2007;49(4):A39.
12. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation 2011;26(4):1327-39. [MEDLINE: 21148030]
13. Urena PA, Kopyt NP, Rodriguez M, Bridges IM, Dehmel B, Cooper K, et al. Efficacy of cinacalcet combined with low dose vitamin D in incident hemodialysis subjects with secondary hyperparathyroidism [abstract no: LB-PO3145]. Journal of the American Society of Nephrology 2011;22(Abstracts):3B.
14. Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S, et al. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Therapeutic Apheresis & Dialysis 2008;12(2):117-25. [: 18387159]
15. Akiba T, Akizawa T, Uchida E, Tsukamoto Y, Koshikawa S, KRN1493 Study Group. Randomized, double blind, placebo-controlled, dose-finding parallel study for KRN1493 (cinacalcet HC1) in Japanese hemodialysis patients [abstract no: F-PO764]. Journal of the American Society of Nephrology 2005;16:503A.
16. Akizawa T, Koshikawa S. Clinical study of cinacalcet in Japan. Therapeutic Apheresis & Dialysis 2008;12 Suppl 1:S13-5. [MEDLINE: 19032520]
17. Block GA, Martin KJ, Turner SA, Avram MM, Hercz G, Abu-Alfa AK, et al. Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO743]. Journal of the American Society of Nephrology 2003;14(Nov):461A. [CENTRAL: CN-00644280]
18. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New England Journal of Medicine 2004;350(15):1516-25. [MEDLINE: 15071126]
19. Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, et al. Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]. Journal of the American Society of Nephrology 2003;14(Nov):464A.
20. Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P, et al. The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:219. [: CN-00509144]
21. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international 2005;68(4):1793-800. [MEDLINE: 16164656]
22. Frazao JM, Holzer H, Stummvoll HK, Bahner U, Wilkie M, Zani V, et al. Cinacalcet (Mimpara. © /Sensipar. © ) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v89.
23. Frazao JM, Messa P, Cunningham J, Evenepoel P, Shahapuni I, Urena P, et al. Early use of cinacalcet (Mimpara. © /Sensipar. © ) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv8.
24. Frazao JM, Nicolini M, Torresgrossa JV, Kerr P, Jaeger PH, Sprague SM, et al. Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT) [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:219.
25. Goodman WG, Fadda GZ, Finkelstein FO Mittman N, Lien YH, LeBlanc M, et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]. Journal of the American Society of Nephrology 2003;14(Program & Abstracts):460A.
26. Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al. Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]. Journal of the American Society of Nephrology 2004;15(Oct):863A. [CENTRAL: CN-00644149]
27. Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al. Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]. Journal of the American Society of Nephrology 2004;15(Oct):280A. [CENTRAL: CN-00644151]
28. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation 2005;20(6):1232-7. [MEDLINE: 15840675]
29. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism [abstract no: W-PO40084]. Nephrology 2005;10(Suppl 1):A301.
30. Martin KJ, Sherrard DJ, Nassar G, Campbell P, Curzi M, McCary KJ, et al. Control of bio-intact parathyroid hormone (PTH) levels with the calcimimetic Cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO747]. Journal of the American Society of Nephrology 2003;14(Nov):462A. [CENTRAL: CN-00583599]
31. Mittman N, de Francisco ALM, Drueke T, Fadda GZ, Arruda JA, Abu-Alfa AK, et al. Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]. American Journal of Kidney Diseases 2004;43(4):A33.
32. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney international 2005;67(2):760-71. [CENTRAL: 15673327]
33. Sterrett JF, Strom J, Stummvoll HK, Bahner U, Disney A Soroka SD, et al. Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet (SensiparTM) in patients receiving dialysis [abstract]. Journal of the American Society of Nephrology 2004;15(Abstracts):275A. [CENTRAL: CN-00583604]
34. Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clinical Nephrology 2007;68(1):10-7. [MEDLINE: 17703830]
35. de Francisco A, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, et al. Greater achievement of NKF-K/DOQI bone metabolism and disease targets with oral cinacalcet HCL in an EU/Australian phase 3 study in haemodialysis subjects [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:319.
36. de Francisco AL, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, et al. Oral cinacalcet HCI (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): results of a European/Australian phase 3 study. [abstract no: SA-PO742]. Journal of the American Society of Nephrology 2003;14(Nov):461A. [CENTRAL: CN-00583675]
37. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. American Journal of Kidney Diseases 2005;46(1):58-67. [MEDLINE: 15983958]
38. Coburn JW, Charytan C, Chonchol M, Herman J, Lien YH, Liu W, et al. Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis [abstract]. Journal of the American Society of Nephrology 2003;14(Program & Abstracts):460A.
39. Chonchol M, Kopyt N, Herman J, Charytan C, Pischette V, Olson KA, et al. Cinacalcet HCI reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD) [abstract no: 18]. American Journal of Kidney Diseases 2004;43(4):A19. [CENTRAL: CN-00602122]
40. Chonchol M, Locatelli F, Abboud H, Charytan C, De Francisco A, Jolly S, et al. A randomized, double-blind, placebo-controlled study of cinacalcet in CKD not on dialysis [abstract no: SA-PO867]. Journal of the American Society of Nephrology 2007;18(Abstracts):533A. [CENTRAL: CN-00583853]
41. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. American Journal of Kidney Diseases 2009;53(2):197-207. [MEDLINE: 19110359]
42. El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Therapeutic Apheresis & Dialysis 2011;15(6):547-55. [MEDLINE: 22107691]
43. Chertow G, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W, et al. Evaluation of cinacalcet HCI therapy to lower cardiovascular events (EVOLVE) trial [abstract no: PUB359]. Journal of the American Society of Nephrology 2006;17(Abstracts):893A. [CENTRAL: CN-00601998]
44. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, et al. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology Dialysis Transplantation 2012;27(7):2872-9. [MEDLINE: 22529163]
45. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clinical Journal of The American Society of Nephrology: CJASN 2007;2(5):898-905. [MEDLINE: 17702710]
46. Evolve Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New England Journal of Medicine 2012;367(26):2482-94. [MEDLINE: 23121374]
47. Akizawa T, Koshikawa S. Clinical study of cinacalcet in Japan. Therapeutic Apheresis & Dialysis 2008;12 Suppl 1:S13-5. [MEDLINE: 19032520]
48. Fukagawa M, Yumita S, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, et al. Randomized, placebo-controlled trial of cinacalcet (KRN1493) in Japanese dialysis patients with more severe hyperparathyroidism and longer dialysis vintage [abstract no: FP453]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi171.
49. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrology Dialysis Transplantation 2008;23(1):328-35. [MEDLINE: 17717030]
50. Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Koshikawa S, KRN1493 Study Group. A randomized, double blind, placebo-controlled, 14 week study to assess the efficacy and safety of cinacalcet HCI in Japanese hemodialysis patients [abstract no: PUB348]. Journal of the American Society of Nephrology 2006;17(Abstracts):889A.
51. Goodman WG, Frazao JM, Goodkin DA, Turner S, Liu W, Coburn JW. The calcimimetic, R-568, lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):619A-20A. [CENTRAL: CN-00626084]
52. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney International 2000;58(1):436-45. [MEDLINE: 10886592]
53. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. Multiple doses of the calcimimetic AMG 073 reduce plasma parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT) [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):576A.
54. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology 2002;13(4):1017-24. [MEDLINE: 11912261]
55. Harris RZ, Padhi D, Marbury TC, Novelck RJ, SalfiM, Sullivan JT. Pharmacokinetics, pharmacodynamics and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. American Journal of Kidney Diseases 2004;44(6):1070-6. [MEDLINE: 15558528]
56. Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation 2012;27(5):1942-9. [MEDLINE: 21931122]
57. Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation 2012;27(8):3270-8. [MEDLINE: 22387567]
58. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney International 2003;63(1):248-54. [MEDLINE: 12472790]
59. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Turner SA, Blaisdell PW, et al. The calcimimetic AMG073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium x phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism (SHPT) [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):578A. [CENTRAL: CN-00626121]
60. Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, et al. Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]. Journal of the American Society of Nephrology 2003;14(Nov):464A.
61. Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P, et al. The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:219. [CENTRAL: CN-00509144]
62. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international 2005;68(4):1793-800. [MEDLINE: 16164656]
63. Frazao JM, Holzer H, Stummvoll HK, Bahner U, Wilkie M, Zani V, et al. Cinacalcet (Mimpara. © /Sensipar. © ) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v89.
64. Frazao JM, Messa P, Cunningham J, Evenepoel P, Shahapuni I, Urena P, et al. Early use of cinacalcet (Mimpara. © /Sensipar. © ) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv8.
65. Frazao JM, Nicolini M, Torresgrossa JV, Kerr P, Jaeger PH, Sprague SM, et al. Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT). 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:219.
66. Goodman WG, Fadda GZ, Finkelstein FO, Mittman N, Lien YH, LeBlanc M, et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]. Journal of the American Society of Nephrology 2003;14(Program & Abstracts):460A.
67. Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al. Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]. Journal of the American Society of Nephrology 2004;15(Oct):863A. [CENTRAL: CN-00644149]
68. Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al. Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]. Journal of the American Society of Nephrology 2004;15(Oct):280A. [CENTRAL: CN-00644151]
69. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology 2005;16(3):800-7. [MEDLINE: 15689407]
70. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Phase 3 experience with cinacalcet HCI in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT [abstract no: SA-PO752]. Journal of the American Society of Nephrology 2003;14(Nov):463A. [CENTRAL: CN-00626029]
71. Mittman N, Finkelstein F, Culleton B, Charytan C, Agarwal A, Albizem MA, et al. Cinacalcet HCI (SensiparTM) for the management of secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) [abstract no: F-PO985]. Journal of the American Society of Nephrology 2004;15(Oct):280A. [CENTRAL: CN-00626108]
72. Mittman N, de Francisco AL, Drueke T, Fadda GZ, Arruda JA, Abu-Alfa AK, et al. Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]. American Journal of Kidney Diseases 2004;43(4):A33.
73. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney international 2005;67(2):760-71. [MEDLINE: 15673327]
74. Cunningham J, Chertow G, Goodman W, Danese M, Olson K, Klassen P, et al. The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:219. [CENTRAL: CN-00509144]
75. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international 2005;68(4):1793-800. [MEDLINE: 16164656]
76. Goodman WG, de Francisco AL, Mittman N, Messa P, Lien YH, Leblanc M, et al. Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]. Journal of the American Society of Nephrology 2004;15(Oct):863A. [CENTRAL: CN-00644149]
77. Goodman WG, de Francisco AL, Moe SM, Cunningham J, Martin KJ, McCary LC, et al. Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]. Journal of the American Society of Nephrology 2004;15(Oct):280A. [CENTRAL: CN-00644151]
78. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clinical Nephrology 2008;69(4):269-78. [MEDLINE: 18397701]
79. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:218-9. [CENTRAL: CN-00509338]
80. Frazao JM, Braun J, Messa P, Dehmel B, Mattin C, Wilkie M. Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?. BMC Nephrology 2012;13:76. [MEDLINE: 22863242]
81. Frazao JM, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The Optima Study: earlier intervention of cinacalcet HCL (Sensipar. © /Mimpara. © ) enables greater achievement of KDOQIT secondary hyperparathyroidism (SHPT) targets in dialysis patients [abstract no: 45]. American Journal of Kidney Diseases 2006;47(4):A30. [CENTRAL: CN-00644220]
82. Gonzalez MT, Hutchison AJ, Girndt M, Stahl-Nilsson A, Zani V, Carter D, et al. Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (Mimpara. © /Sensipar. © ) [abstract no: SP359]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv134.
83. Locatelli F, Macario F, Brink HS, Dhaene M, Pai P, Holzer H, et al. The OPTIMA study: efficacy of a cinacalcet (Mimpara. © /Sensipar. © ) treatment algorithm to treat dialysis patients with elevated PTH and calcium-phosphorus product (Ca x P) [abstract no: SP357]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv133. [CENTRAL: CN-00644212]
84. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(1):36-45. [MEDLINE: 18178780]
85. Messa P, Motellon JL, OPTIMA Study Group. Optimizing the use of cinacalcet (Mimpara. © /Sensipar. © ) and vitamin D: interim results from the OPTIMA study [abstract no: F-PO758]. Journal of the American Society of Nephrology 2005;16:501A-2A. [CENTRAL: CN-00644221]
86. Messa P, Villa G, Braun J, Maduell F, Cruz J, Martin PY, et al. The OPTIMA study: lower doses of cinacalcet (Mimpara. © /Sensipar. © ) are required to achieve KDOQITM secondary hyperparathyroidism (HPT) targets in dialysis patients with less severe disease [abstract no: MP324]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv407. [CENTRAL: CN-00583842]
87. Perrault L, Carter D, Molemans B, Maetzel A. Use of cinacalcet HCL (Mimpara. © /Sensipar. © ) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT): a cost-consequence analysis of cinacalcet HCL versus standard of care (SC) [abstract no: SP363]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv136.
88. Wilkie M. A multi-centre, randomised, open-label study to compare the efficacy and safety of an oral calcimimetic agent (AMG 073) when two different vitamin D regimens are used in subjects with secondary hyperparathyroidism of end-stage renal disease (ESRD). http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0059124801 (accessed 1 June 2014).
89. Wilkie M, Pontoriero G, Macario F, Yaqoob M, Bouman K, Braun J, et al. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron 2009;112(1):c41-50. [MEDLINE: 19365139]
90. Wilkie M, Salvadori M, De Meester J, Jofre R, Koopman MG, Leidig FM, et al. The OPTIMA study: optimising the dose of vitamin D (vit D) in the presence of cinacalcet (Mimpara. © /Sensipar. © ) to obtain maximum clinical benefit [abstract no: SP358]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv134. [CENTRAL: CN-00583844]
91. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Journal of the American Society of Nephrology 2003;14(3):575-83. [MEDLINE: 12595492]
92. Al-Hilali N, Hussain N, Kawy YA, Al-Azmi M. A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases & Transplantation 2011;22(3):448-55. [MEDLINE: 21566299]
93. Coburn JW, Barri YM, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):573A-4A. [CENTRAL: CN-00550686]
94. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clinical Journal of The American Society of Nephrology: CJASN 2006;1(2):305-12. [MEDLINE: 17699221]
95. Reed J, Keightley G, Blumenthal S, Bradley C, LaBrecque J, Turner S, et al. The CONTROL STUDY: enhanced achievement of NKF-K/DOQI bone metabolism and disease targets using cinacalcet HCL (Sensipar) [abstract]. Journal of the American Society of Nephrology 2004;15(Abstracts):280A.
96. Cunningham J, Holzer H, Reichel H, Braun J, Hawley C, Urena P, et al. Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SPTH) [abstract no: M479]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):150-1. [CENTRAL: CN-00583594]
97. Cunningham J, Urena P, Reichel H, Holzer H, Drueke T, Zani V, et al. Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD) [abstract no: SP210]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v89.
98. De Francisco A, Evenepoel P, Brink HS, Mellotte G, Barata JD, Zani V, et al. Cinacalcet (Mimpara. © /Sensipar. © ) effectively reduces intact parathyroid hormone (iPTH) and serum calcium (CA) regardless of serum calcium level in patients with secondary hyperparathyroidism (HPT) [abstract no: MO30]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v197.
99. Harris R, Padhi D, SalfiM, Yates W, Simiens MA, Sulivan JT. Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCI up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD) [abstract no: SA-PO746]. Journal of the American Society of Nephrology 2003;14(Nov):462A. [CENTRAL: CN-00583298]
100. Kaperonis N, Kourvelou C, Sgantzos A, Nastou D, Ntatsis G, Ziakka S, et al. Cinacalcet vs. paricalcitol in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii497-8.
101. Moe SM, Sprague SM, Cunningham J, Drueke T, Adler S, Rosansky SJ, et al. Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCI [abstract no: SA-PO753]. Journal of the American Society of Nephrology 2003;14:463A-4A.
102. BelozeroffV, Goodman W, Ren L, Kalantar-Zadeh K. Cinacalcet lowers serum alkaline phosphatase (alkPhos) in maintenance hemodialysis (MHD) patients [abstract no: SA-PO698]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):495A-6A.
103. Bushinsky DA, Avram MM, Abu-Alfa AK, Borah MF, Shapiro WB, Olson KA, et al. Characterization of the effects of cinacalcet HC1 (Sensipar. © /Mimpara. © ) on serum calcium in dialysis patients with secondary hyperparathyroidism (HPT) [abstract no: F-PO756]. Journal of the American Society of Nephrology 2005;16:501A. [CENTRAL: CN-00583862]
104. Moe SM, Coburn JW, Quarles LD, Goodman WG, Chertow GM, Block GA, et al. Achievement of proposed NKF-K/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (HPT) [abstract no: SU-FC217]. Journal of the American Society of Nephrology 2003;14(Nov):48A.
105. Moe SM, Goodman WG, Cunningham J, Drueke T, Adler S, Rosansky SJ, et al. Cinacalcet HC1 sustains long-term control of secondary hyperparathyroidism (HPT) [abstract no: F-PO755]. Journal of the American Society of Nephrology 2005;16:501A.
106. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrology Dialysis Transplantation 2005;20(10):2186-93. [MEDLINE: 16030053]
107. Padhi D, Harris R, SalfiM, Yates W, Hansen J, Flynn J, et al. Cinacalcet HCI absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCI, and calcium carbonate). [abstract no: SA-PO744]. Journal of the American Society of Nephrology 2003;14:461A.
108. Pahl M, Jara A, Bover J, Rodriguez M, Felsenfeld AJ. The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients. Kidney international 1996;49(1):226-31. [MEDLINE: 8770972]
109. Quarles LD, Zeig S, Spiegel DM, Silver MR, Vokes TJ, Torregrosa JV, et al. Cinacalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity [abstract]. Journal of the American Society of Nephrology 2003;14(Program & Abstracts):463A.
110. Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sanchez GM, et al. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clinical Nephrology 2008;70(2):126-34. [MEDLINE: 18793528]
111. Schaefer RM, Bover J, Kleophas W, Sanz D, Asensio C, Alonso JL, et al. The SENSOR study: a study to evaluate the efficacy of administering cinacalcet (Mimpara. © /Sensipar. © ) with the first meal after dialysis [abstract no: MO003]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv288. [CENTRAL: CN-00671819]
112. Sezer S, Tutal E, Bal Z, Ozelsancak R, Demirci BG, Torun D, et al. Treatment of secondary hyperparathyroidism in maintenance hemodialysis patients: a randomised clinical trial comparing paricalcitol, calcitriol and cinacalcet [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii509-10.
113. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrology Dialysis Transplantation 2008;23(7):2311-8. [MEDLINE: 18310602]
114. Chertow GM, Corpier C, Zieg S, Stegman M, Lynn R, Abu-Alfa AK, et al. Preliminary results from TARGET: treatment strategies to achieve recommended K/DOQI goals in ESRD patients on Cinacalcet [abstract]. Journal of the American Society of Nephrology 2004;15(Abstracts):863A.
115. Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, et al. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis International 2012;16(2):188-97. [MEDLINE: 22118402]
116. Coburn JW, Charytan C, Chonchol M, Herman J, Lien YH, Liu W, et al. Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney diseases (CKD) not receiving dialysis [abstract]. Journal of the American Society of Nephrology 2003;14(Program & Abstracts):460A.
117. Drueke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen MG, et al. Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073 [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):764A. [CENTRAL: CN-00550690]
118. Fournier A, Pontoiero G, Walker R, Martin-Malo A, Wilkie M, Coyne DW, et al. Cinacalcet HCL reduces parathyroid hormone (PTH) and calcium-phosphate product (Ca x P) regardless of concurrent changes in vitamin D administration [abstract]. 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal). 2004:319. [CENTRAL: CN-00509198]
119. University of Pennsylvania, Renal Electrolyte, Hypertension Division. 2004. A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of a calcimimetic agent (AMG 073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency. http://www.uphs.upenn.edu/renal/research/clinical_research_chronic_kidney.html (accessed 2 June 2014).
120. Albaaj F, Hutchison A. Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003;63(6):577-96. [MEDLINE: 12656655]
121. Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. American Journal of Kidney Diseases 1996;28(6):924-30. [MEDLINE: 8957048]
122. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584-90. [MEDLINE: 9718377]
123. Block GA, Klassen PS, Lazarus LM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology 2004;15(8):2208-10. [MEDLINE: 15284307]
124. Borrows R, Loucaidou M, Van Tromp J, Cairns T, Griffith M, Hakim N, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. American Journal of Transplantation 2004;4(11):1845-51. [MEDLINE: 15476485]
125. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999;282(8):771-8. [MEDLINE: 10463714]
126. Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR. Lower probability of patient survival with continuous peritoneal dialysis in the united states compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Journal of the American Society of Nephrology 1997;8(6):965-71. [MEDLINE: 9189865]
127. Courant O, Letessier E, Moutel MG, Hamy A, Paineau J, Visset J. Surgical treatment of secondary hyperparathyroidism in chronic kidney failure. Results of total parathyroidectomy with parathyroid autotransplantation. Journal de Chirurgie 1993;130(8-9):327-34. [MEDLINE: 8253879]
128. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international 2005;68(4):1793-800. [MEDLINE: 16164656]
129. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316(7124):61-6. [MEDLINE: 9451274]
130. US Food, Drug Administration. Sensipar (cinacalcet HCl) tablets. http://www.fda.gov/safety/medwatch/safetyinformation/ucm194427.htm (accessed 2 June 2014).
131. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patient. Journal of the American Society of Nephrology 2001;12(10):2131-8. [MEDLINE: 11562412]
132. Guyatt GH, Oxman A D, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
133. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
134. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
135. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney international 1995;26(5):622-31. [MEDLINE: 8264137]
136. Juni P, Sterchi R, Dieppe P. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity. BMJ 2003;326(7384):334. [MEDLINE: 12574052]
137. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International - Supplement 2013;3:1-150.
138. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, et al. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney International 2004;65(1):282-8. [MEDLINE: 14675061]
139. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. Journal of the American Society of Nephrology 2005;16(2):520-8. [MEDLINE: 15615819]
140. KHA-CARI guidelines. http://www.cari.org.au/(accessed 2 June 2014).
141. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70. [MEDLINE: 12775614]
142. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. Nephrology Dialysis Transplantation 2004;19 Suppl 1:i9-13. [MEDLINE: 15126648]
143. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney International - Supplement 2003;85:S111-4. [MEDLINE: 12753279]
144. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, et al. Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy. American Journal of Kidney Diseases 2004;43(3):558-65. [MEDLINE: 14981615]
145. McMahon LP, Roger SD, Levin A, SLIMHEART Investigators Group. Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease. Journal of the American Society of Nephrology 2004;15(6):1640-7. [MEDLINE: 15153576]
146. Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB Journal 2006;20(14):2562-4. [MEDLINE: 17077282]
147. Mizobuchi M, Ogata H, Hatamura I, Saji F, Koiwa F, Kinugasa E, et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochemical & Biophysical Research Communications 2007;362(1):11-6. [MEDLINE: 17706605]
148. NICE: National Institute for Health and Care Excellence. TA117 Hyperparathyroidism - cinacalcet guidance (24 January 2007). http://guidance.nice.org.uk/TA117/Guidance/(accessed 2 June 2014).
149. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases 2003;42(4 Suppl 3):S1-210. [MEDLINE: 14520607]
150. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282(8):786-90. [MEDLINE: 10463718]
151. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. American Journal of Kidney Diseases 1995;26(4):622-31. [MEDLINE: 7573017]
152. Simes RJ. Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology 1986;4(10):1529-41. [MEDLINE: 3760920]
153. Stehman-Breen C. Osteoporosis and chronic kidney disease. Seminars in Nephrology 2004;24(1):78-81. [MEDLINE: 14730513]
154. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. Journal of the American Society of Nephrology 2004;15(3):770-9. [MEDLINE: 14978180]
155. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 1999;282(8):790-5. [MEDLINE: 10463719]
156. Urena P, Frazao JM. Calcimimetic agents: review and perspectives. Kidney International - Supplement 2003;85:S91-6. [MEDLINE: 12753275]
157. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. United States Renal Data System 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. American Journal of Kidney Diseases 2013;61(1 Suppl 1):e1-e480.
158. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. American Journal of Kidney Diseases 1995;26(5):836-44. [MEDLINE: 7485142]
159. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases 2006;48(3):392-401. [MEDLINE: 16931212]
160. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatrica 2000;89(6):666-71. [MEDLINE: 10914959]
161. Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Medicine 2013;10(4):e1001436. [MEDLINE: 23637579]
162. Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006254]
163. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. American Journal of Kidney Diseases 2006;47(5):715-26. [MEDLINE: 16632010]